<DOC>
	<DOC>NCT01839500</DOC>
	<brief_summary>This prospective, multi-center, non-interventional study will evaluate the efficacy and safety of Herceptin (trastuzumab) in routine clinical practice in Chinese patients with gastric or gastro-oesophageal cancer. Treatment patterns and clinical outcomes in patients with gastric cancer in China will be evaluated. Data will be collected from eligible patients for up to 6 years.</brief_summary>
	<brief_title>EVIDENCE: A Non-Interventional Study of Treatment and Clinical Outcomes in Chinese Patients With Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>Histologically confirmed cancer of the stomach or gastrooesophageal junction or recurrent disease within 6 months before the date of recruitment Documented patient with trackable medical records HER2 IHC status is known Cohort I/II/IV: Patients with mGC: with recurrent or metastatic disease or with inoperable locally advanced disease Cohort III/V: Patients with operable nonmGC: TxNxM0 (according to AJCC edition 7th) Patients receiving regimen in a blinded trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>